Increased levels of high sensitive Troponin-T after first dose of Adriamycin containing therapy may predict brain-type natriuretic rise after 6 months in patients with breast carcinoma
DOI:
https://doi.org/10.37609/srinmed.67Anahtar Kelimeler:
Anthracycline- cardiotoxicity- highly sensitive troponin T- Breast CancerÖz
Objective: In this study, we aimed to investigate the usefulness of highly sensitive troponin-T (hs-TnT) levels for the early prediction of anthracycline-related cardiac stress and subclinical cardiac dysfunction.
Method: Patients newly diagnosed with breast cancer with normal cardiac function were randomized to our study. All patients had taken 240 mg/m2 adriamycin in 12 weeks. Brain-type natriuretic peptide (BNP) and hs-TnT levels were measured; echocardiography and tissue Doppler imaging was performed to all patients for 4 times: at baseline, 4-12 hours after first adriamycin dose, at 3 months and at 6 months.
Results: A total of 43 women (52.7±12.1 years) with breast cancer were included in our study. Brain natriuretic peptide elevation was observed in 8 patients, in which 2 of them showed symptoms and signs of overt heart failure. In the logistic regression analysis, hs-TnT levels (OR: 1.154; (0.974–1.336 in 95% CI) and BNP levels (OR: 1.009 (1.001-1.018 in 95 % CI) measured 12–24 hours after first adriamycin dose were independently associated with BNP rise at 6th month. Receiver operating curve analysis revealed a cut-off value of 12.85 ng/L for hs-TnT levels to predict BNP elevation at 6th month with 62.5% sensitivity and 85.7% specificity.
Conclusion: hs-TnT levels after first dose of adriamycin containing therapy higher than 18.65 ng/L was associated with BNP elevation at 6th month with a specificity of 97.1% in our patient group. Early hs-TnT elevation may represent a potential marker of chemotherapy-related cardiac dysfunction.
İndirmeler
Referanslar
Torre, L. A., Bray, F., Siegel, R. L., Ferlay, J., Lortet-Tieulent, J., & Jemal, A. (2015). Global cancer statis-tics, 2012. CA: A Cancer Journal for Clinicians, 65(2), 87–108. https://doi.org/10.3322/caac.21262
Cortazar P, Zhang L, Untch M, Mehta K, Constantino JP, Wolmark N, et al. Pathological complete re-sponse and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet 2014;384(9938): 164-72. https://doi.org/10.1016/S0140-6736(13)62422-8
Chang HR. Trastuzumab-based neoadjuvant therapy in patients with HER2-positive breast cancer. Cancer 2010;116(12): 2856-67. https://doi.org/10.1002/cncr.25120
Hernandez-Aya LF, Gonzalez-Angulo AM. Adjuvant systemic therapies in breast cancer. Surg Clin North Am 2013;93(2): 473-91. https://doi.org/10.1016/j.suc.2012.12.002
Ades F, Zardavas D, Pinto AC, Criscitiello C, Aftimos P, de Azambuja E. Cardiotoxicity of systemic agents used in breast cancer. Breast 2014;23(4): 317-28. https://doi.org/10.1016/j.breast.2014.04.002
Sawyer DB. Anthracyclines and heart failure. N Engl J Med 2013;368(12): 1154-6. https://doi.org/10.1056/NEJMcibr1214975
Sawaya H, Sebag IA, Plana JC, Januzzi JL, Ky B, Cohen V, et al. Early detection and prediction of cardio-toxicity in chemotherapy-treated patients. Am J Cardiol 2011;107(9): 1375-80. https://doi.org/10.1016/j.amjcard.2011.01.006
Dodos F, Halbsguth T, Erdmann E, Hoppe UC. Usefulness of myocardial performance index and bio-chemical markers for early detection of anthracycline-induced cardiotoxicity in adults. Clin Res Car-diol 2008;97(5): 318-26. https://doi.org/10.1007/s00392-007-0633-6
Kilickap S, Barista I, Akgul E, Aytemir K, Aksoyek S, Aksoy S, et al. cTnT can be a useful marker for early detection of anthracycline cardiotoxicity. Ann Oncol 2005;16(5): 798-804. https://doi.org/10.1093/annonc/mdi152
Thavendiranathan P, Poulin F, Lim KD, Plana JC, Woo A, Marwick TH. Use of myocardial strain imag-ing by echocardiography for the early detection of cardiotoxicity in patients during and after cancer chemotherapy: a systematic review. J Am Coll Cardiol 2014;63(25 Pt A): 2751-68. https://doi.org/10.1016/j.jacc.2014.01.073
Korzeniowska K, Jankowski J, Cieslewicz A, Jablecka A. Current approach for detection of sub-clinical left ventricular dysfunction associated with chemotherapy. Pharmacol Rep 2015;67(6): 1098-102. https://doi.org/10.1016/j.pharep.2015.03.010
Monsuez JJ. Detection and prevention of cardiac complications of cancer chemotherapy. Arch Cardi-ovasc Dis 2012;105(11): 593-604. https://doi.org/10.1016/j.acvd.2012.04.008
Cardinale D, Sandri MT, Martinoni A, Broghini E, Civelli M, Lamantia G, et al. Myocardial injury re-vealed by plasma troponin I in breast cancer treated with high-dose chemotherapy. Ann Oncol 2002;13(5): 710-5. https://doi.org/10.1093/annonc/mdf170
de Lemos JA, Drazner MH, Omland T, Ayers CR, Khera A, Rohatgi A, et al. Association of troponin T de-tected with a highly sensitive assay and cardiac structure and mortality risk in the general population. JAMA 2010;304(22):2503-12. https://doi.org/10.1001/jama.2010.1768
World Medical A. World Medical Association Declaration of Helsinki: ethical principles for medical re-search involving human subjects. JAMA 2013;310(20): 2191-4. https://doi.org/10.1001/jama.2013.281053
Lang RM, Bierig M, Devereux RB, Flachskampf FA, Foster E, Pellikka PA, et al. Recommendations for chamber quantification: a report from the American Society of Echocardiography’s Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr 2005;18(12): 1440-63. https://doi.org/10.1016/j.echo.2005.10.005
Quinones MA, Otto CM, Stoddard M, Waggoner A, Zoghbi WA; Recommendations for quantification of Doppler echocardiography: a report from the Doppler Quantification Task Force of the Nomencla-ture and Standards Committee of the American Society of Echocardiography. J Am Soc Echocardiogr 2002;15(2): 167-84. https://doi.org/10.1067/mje.2002.120202
Hossain A, Chen A, Ivy P, Lenihan DJ, Klatman J, Taddei-Peters W, et al. The importance of clinical grading of heart failure and other cardiac toxicities during chemotherapy: updating the common ter-minology criteria for clinical trial reporting. Heart Fail Clin 2011;7(3): 373-84. https://doi.org/10.1016/j.hfc.2011.03.008
Kapusta L, Thijssen JM, Groot-Loonen J, Antonius T, Mulder J, Daniels O. Tissue Doppler imaging in detection of myocardial dysfunction in survivors of childhood cancer treated with anthracyclines. Ul-trasound Med Biol 2000;26(7): 1099-108. https://doi.org/10.1016/S0301-5629(00)00252-0
Aurigemma GP, Gottdiener JS, Shemanski L, Gardin J, Kitzman D. Predictive value of systolic and dias-tolic function for incident congestive heart failure in the elderly: the cardiovascular health study. J Am Coll Cardiol 2001;37(4): 1042-8. https://doi.org/10.1016/S0735-1097(01)01110-X
Morandi P, Ruffini PA, Benvenuto GM, La Vecchia L, Mezzena G, Raimondi R. Serum cardiac troponin I levels and ECG/Echo monitoring in breast cancer patients undergoing high-dose (7 g/m(2)) cyclo-phosphamide. Bone Marrow Transplant 2001;28(3): 277-82. https://doi.org/10.1038/sj.bmt.1703132
Marchandise B, Schroeder E, Bosly A, Doyen C, Weynants P, Kremer R, et al. Early detection of doxo-rubicin cardiotoxicity: interest of Doppler echocardiographic analysis of left ventricular filling dynam-ics. Am Heart J 1989;118(1): 92-8. https://doi.org/10.1016/0002-8703(89)90077-X
Ommen SR, Nishimura RA, Appleton CP, Miller FA, Oh JK, Redfield MM, et al. Clinical utility of Doppler echocardiography and tissue Doppler imaging in the estimation of left ventricular filling pressures: A comparative simultaneous Doppler-catheterization study. Circulation 2000;102(15): 1788-94. https://doi.org/10.1161/01.CIR.102.15.1788
Bu’Lock FA, Mott MG, Oakhill A, Martin RP. Early identification of anthracycline cardiomyopathy: pos-sibilities and implications. Arch Dis Child 1996;75(5): 416-22. https://doi.org/10.1136/adc.75.5.416
Lipshultz SE, Rifai N, Sallan SE, Lipsitz SR, Dalton V, Sacks DB, et al. Predictive value of cardiac tro-ponin T in pediatric patients at risk for myocardial injury. Circulation 1997;96(8): 2641-8. https://doi.org/10.1161/01.CIR.96.8.2641
Adamcova M, Lencova-Popelova O, Jirkovsky E, Mazurova Y, Palicka V, Simko F, et al. Experimental determination of diagnostic window of cardiac troponins in the development of chronic anthracycline cardiotoxicity and estimation of its predictive value. Int J Cardiol 2015;201: 358-67. https://doi.org/10.1016/j.ijcard.2015.07.103
Pourier MS, Kapusta L, van Gennip A, Bökkerink JP, Loonen J, Bellersen L, et al. Values of high sensi-tive troponin T in long-term survivors of childhood cancer treated with anthracyclines. Clin Chim Acta 2015;441: 29-32. https://doi.org/10.1016/j.cca.2014.12.011
Thygesen K, Mair J, Mueller C, Huber K, Weber M, Plebani M, et al. Recommendations for the use of natriuretic peptides in acute cardiac care: a position statement from the Study Group on Biomarkers in Cardiology of the ESC Working Group on Acute Cardiac Care. Eur Heart J 2012;33(16): 2001-6. https://doi.org/10.1093/eurheartj/ehq509
Suzuki T, Hayashi D, Yamazaki T, Mizuno T, Kanda Y, Komuro I, et al. Elevated B-type natriuretic peptide levels after anthracycline administration. Am Heart J 1998;136(2): 362-3. https://doi.org/10.1053/hj.1998.v136.89908
Nousiainen T, Jantunen E, Vanninen E, Remes J, Vuolteenaho O, Hartikainen J. Natriuretic peptides as markers of cardiotoxicity during doxorubicin treatment for non-Hodgkin’s lymphoma. Eur J Haematol 1999;62(2): 135-41. https://doi.org/10.1111/j.1600-0609.1999.tb01734.x
Hayakawa H, Komada Y, Hirayama M, Hori H, Ito M, Sakurai M. Plasma levels of natriuretic peptides in relation to doxorubicin-induced cardiotoxicity and cardiac function in children with cancer. Med Pedi-atr Oncol 2001;37(1): 4-9. https://doi.org/10.1002/mpo.1155
İndir
Yayınlanmış
Sayı
Bölüm
Lisans
Telif Hakkı (c) 2026 Scientific Reports in Medicine
Bu çalışma Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License ile lisanslanmıştır.
The Journal and content of this website is licensed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) License. This is in accordance with the Budapest Open Access Initiative (BOAI) definition of open access. The Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) allows users to copy, distribute and transmit unmodified article, and make noncommercial use of the article. The CC BY license permits non-commercial re-use of an open access article, as long as the author is properly attributed.
